Search research articles
Contact Us
Filters
Showing results (11-20 of 328) with videos related to
Page
of 33
Sort By:
Alzheimer'S Research & Therapy
|
December 6, 2014
Biomarkers in biological fluids for dementia with Lewy bodies
Sebastian Schade, Brit Mollenhauer
Nature Reviews. Neurology
|
April 7, 2021
Prodromal Parkinson disease - time is brain
Sandrina Weber, Brit Mollenhauer
Journal of Immunological Methods
|
August 15, 2015
Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid
Niels Kruse, Brit Mollenhauer
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 5, 2010
CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies
Brit Mollenhauer, Michael G Schlossmacher
The Lancet. Neurology
|
December 20, 2024
Movement disorders in 2024: peripheral and outside the box
Brit Mollenhauer, Chin-Hsien Lin
Biomarkers in Medicine
|
October 16, 2010
Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials
Michael G Schlossmacher, Brit Mollenhauer
International Review of Neurobiology
|
May 31, 2017
Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease
Iskandar Johar, Brit Mollenhauer, Dag Aarsland
Movement Disorders Clinical Practice
|
April 8, 2020
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Sebastian Schade, Brit Mollenhauer, Claudia Trenkwalder
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 4, 2018
The importance of an independent validation cohort for metabolomics biomarker studies
Jean-Pierre Trezzi, Karsten Hiller, Brit Mollenhauer
Science (New York, N.Y.)
|
August 18, 2022
Toward preventing Parkinson's disease
Brit Mollenhauer, Christine A F von Arnim
Page
of 33
Search research articles
Search
Showing results (11-20 of 328) with videos related to
Sort By:
Page
of 33
Alzheimer'S Research & Therapy
|
December 6, 2014
Biomarkers in biological fluids for dementia with Lewy bodies
Sebastian Schade, Brit Mollenhauer
Nature Reviews. Neurology
|
April 7, 2021
Prodromal Parkinson disease - time is brain
Sandrina Weber, Brit Mollenhauer
Journal of Immunological Methods
|
August 15, 2015
Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid
Niels Kruse, Brit Mollenhauer
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 5, 2010
CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies
Brit Mollenhauer, Michael G Schlossmacher
The Lancet. Neurology
|
December 20, 2024
Movement disorders in 2024: peripheral and outside the box
Brit Mollenhauer, Chin-Hsien Lin
Biomarkers in Medicine
|
October 16, 2010
Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials
Michael G Schlossmacher, Brit Mollenhauer
International Review of Neurobiology
|
May 31, 2017
Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease
Iskandar Johar, Brit Mollenhauer, Dag Aarsland
Movement Disorders Clinical Practice
|
April 8, 2020
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Sebastian Schade, Brit Mollenhauer, Claudia Trenkwalder
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 4, 2018
The importance of an independent validation cohort for metabolomics biomarker studies
Jean-Pierre Trezzi, Karsten Hiller, Brit Mollenhauer
Science (New York, N.Y.)
|
August 18, 2022
Toward preventing Parkinson's disease
Brit Mollenhauer, Christine A F von Arnim
Page
of 33